News

Mutations of BRCA1 have long been recognized as a cancer stimulant. About five to 10% of breast cancer cases are linked to genetic miscues, half of which are

Drug makers have been trying to find an alternative to protamine, which is thought to have a negative effect on blood pressure which has been linked to increased

Indevus will take over the development and commercialization of Nebido, which recently launched in Europe, in the US. Schering will manufacture and supply commercial product to Indevus. Indevus

The company said its application is expected to receive “priority review” status by the FDA, which means the agency would be required to act on the application within

The firms will evaluate the expression of Scancell’s drug using GTC’s transgenic production platform. GTC says its technology offers significant advantages for the development of proteins that are

The recommendation will form the basis for a European Commission approval, which will enable Noxafil to be marketed in the current 25 EU member states and in Iceland

According to the companies, the trial showed that telbivudine is as effective in chronic hepatitis B patients as the standard treatment lamivudine after one year of use. The

The phase I clinical trial for Cara’s peripherally acting kappa opioid agonist, CR665, demonstrate the treatment to be safe and well-tolerated following intravenous infusion. Furthermore, the resulting plasma

LemnaGene has been researching potential applications of lemna, a small aquatic plant, to produce recombinant proteins. Biolex’s Lex System uses lemna as a transgenic host for the development